The Relationship Between BRCA1 Expression and Grade in Breast Cancer Patients in NTB
Authors
Romy Healthy Mikailla , Novrita Padauleng , Rizka Vidya Lestari , Lale Maulin Prihatina , Bambang Priyanto , Baiq Ratna KumaladewiDOI:
10.29303/jbt.v25i4a.10860Published:
2025-12-22Issue:
Vol. 25 No. 4a (2025): Special IssueKeywords:
BRCA1, Grade, Invasive Breast Carcinoma, NTBArticles
Downloads
How to Cite
Downloads
Metrics
Abstract
Breast cancer is the malignancy with the highest incidence among women in West Nusa Tenggara (NTB). The Breast Cancer 1 (BRCA1) gene is a tumor suppressor gene that plays a crucial role in DNA repair and genome stability. A decrease in BRCA1 expression is theoretically associated with more aggressive tumor characteristics, such as a low degree of differentiation (high grade). However, data regarding the relationship between BRCA1 protein expression and the degree of cell differentiation in the patient population in NTB remains limited. This study employed a cross-sectional design with an observational analytic approach on 50 paraffin block samples from Invasive Breast Carcinoma patients at the NTB Provincial General Hospital from 2022-2023. BRCA1 protein expression was assessed using immunohistochemistry with a positive cut-off defined as staining in >20% of tumor cell nuclei. Data on the degree of differentiation (Grade 1, 2, and 3) were obtained from medical records. The relationship between the two variables was analyzed using the Lambda, Pearson’s R, and Spearman Correlation tests with a significance level of p < 0.05. The majority of samples (84%) were grade 3 tumors. The distribution of BRCA1 expression in the total sample was balanced, with 25 cases (50%) showing positive expression and 25 cases (50%) showing negative expression. In the grade 3 subgroup, this distribution remained balanced. Statistical analysis consistently showed no significant relationship between BRCA1 expression and the degree of cell differentiation (p > 0.05).
References
Alacacioglu, A., Varol, U., Kucukzeybek, Y., Somali, I., Altun, Z., Aktas, S. and Tarhan, M.O. (2018) ‘BRCA genes: BRCA 1 and BRCA 2’, JBUON, 23(4), pp. 862–866.
Armes, J.E., Egan, A.J.M., Southey, M.C., Dite, G.S., McCredie, M.R.E., Giles, G.G., Hopper, J.L. and Venter, D.J. (1998) ‘The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: A population-based study’, Cancer, 83(11), pp. 2335–2345. Available at: https://doi.org/10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.0.CO;2-N.
Auclair, Y. and Richard, S. (2013) ‘The role of arginine methylation in the DNA damage response’, DNA Repair, pp. 459–465. Available at: https://doi.org/10.1016/j.dnarep.2013.04.006.
Bagga, N., Agarwal, P., Tuteja, R.K., Mehrotra, R. and Singh, K.R. (2021) ‘Immunohistochemical expression of ER, PR, HER2, Ki67, CK5/6 and BRCA1 in non familial breast cancer and its correlation with clinico-pathological parameters’, Indian Journal of Pathology and Oncology, 8(1), pp. 111–119. Available at: https://doi.org/10.18231/j.ijpo.2021.022.
Bal, A., Verma, S., Joshi, K., Singla, A., Thakur, R., Arora, S. and Singh, G. (2012) ‘BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression’, Virchows Archiv, 461(3), pp. 305–312. Available at: https://doi.org/10.1007/s00428-012-1286-z.
Bane, A.L., Beck, J.C., Bleiweiss, I., et al. (2007) BRCA2 Mutation-associated Breast Cancers Exhibit a Distinguishing Phenotype Based on Morphology and Molecular Profiles From Tissue Microarrays, Am J Surg Pathol. Available at: http://research.nhgri.
Baretta, Z., Mocellin, S., Goldin, E., Olopade, O.I. and Huo, D. (2016) ‘Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis’, Medicine (United States), 95(40). Available at: https://doi.org/10.1097/MD.0000000000004975.
Bouras, T., Pal, B., Vaillant, F., et al. (2008) ‘Notch Signaling Regulates Mammary Stem Cell Function and Luminal Cell-Fate Commitment’, Cell Stem Cell, 3(4), pp. 429–441. Available at: https://doi.org/10.1016/j.stem.2008.08.001.
Ter Brugge, P., Kristel, P., Van Der Burg, E., et al. (2016) ‘Mechanisms of therapy resistance in patient-derived xenograft models of brca1-deficient breast cancer’, Journal of the National Cancer Institute, 108(11). Available at: https://doi.org/10.1093/jnci/djw148.
Buckley, N.E., Nic An Tsaoir, C.B., Blayney, J.K., et al. (2013) ‘BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers’, Nucleic Acids Research, 41(18), pp. 8601–8614. Available at: https://doi.org/10.1093/nar/gkt626.
Clark, S.L., Rodriguez, A.M., Snyder, R.R., Hankins, G.D.V. and Boehning, D. (2012) ‘Structure-function of the tumor suppressor BRCA1’, Computational and Structural Biotechnology Journal. Elsevier B.V., p. e201204005. Available at: https://doi.org/10.5936/csbj.201204005.
Choi, W. and Lee, E.S. (2022) ‘Therapeutic Targeting of DNA Damage Response in Cancer’, International Journal of Molecular Sciences. MDPI. Available at: https://doi.org/10.3390/ijms23031701
Cortez, D., Wang, Y., Qin, J. and Elledge, S.J. (1999) ‘Requirement of ATM-Dependent Phosphorylation of Brcal in the DNA Damage Response to Double-Strand Breaks’, Science, 286, pp. 1162–1166.
Dinesh, K.P.B., Devaraj, H., Murugan, V., Rajaraman, R. and Niranjali, S. (2006) ‘Analysis of loss of heterozygosity and immunohistochemistry in BRCA1 gene in sporadic breast cancers’, Molecular and Cellular Biochemistry, 287(1–2), pp. 177–183. Available at: https://doi.org/10.1007/s11010-005-9097-z.
Dooijeweert, C., van Diest, P.J. and Ellis, I.O. (2022) ‘Grading of invasive breast carcinoma: the way forward’, Virchows Archiv. Springer Science and Business Media Deutschland GmbH, pp. 33–43. Available at: https://doi.org/10.1007/s00428-021-03141-2.
Elston, C.W. and Ellis, O. (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Pathological prognostic factors in breast cancer. 1. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology.
Ennis S Lamon, D.J., Rian Eyland -j Ones, B.L., Teven Hak, S.S., Ank Uchs, H.F., Irginia Aton, V.P., Harm, P.D., Lex Ajamonde, A.B., Homas Leming, T.F., Olfgang Iermann, W.E., Anet Olter, J.W., Ark Egram, M.P., Ose Aselga, J.B. and Arry Orton, L.N. (2001) The New England Journal of Medicine USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER2 Background The HER2 gene, which encodes the, N Engl J Med. Available at: www.nejm.org.
Eras, N., Tuncel, F., Altıntas, Z. and Erden, S. (2024) ‘CLINICOPATHOLOGICAL CHARACTERISTICS AND BRCA1/BRCA2 PATHOGENIC VARIANTS OF PATIENTS WITH BREAST CANCER’, Polish Journal of Pathology, 75(1), pp. 1–7. Available at: https://doi.org/10.5114/pjp.2024.135703.
Fan, F. and Thomas, P.A. (2007) Tumour of The Breast, Cancer Grading Manual.
Fu, X., Tan, W., Song, Q., Pei, H. and Li, J. (2022) ‘BRCA1 and Breast Cancer: Molecular Mechanisms and Therapeutic Strategies’, Frontiers in Cell and Developmental Biology. Frontiers Media S.A. Available at: https://doi.org/10.3389/fcell.2022.813457.
Gorodetska, I., Kozeretska, I. and Dubrovska, A. (2019) ‘BRCA genes: The role in genome stability, cancer stemness and therapy resistance’, Journal of Cancer. Ivyspring International Publisher, pp. 2109–2127. Available at: https://doi.org/10.7150/jca.30410.
Hamajima, N., Hirose, K., Tajima, K., et al. (2012) ‘Menarche, menopause, and breast cancer risk: Individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies’, The Lancet Oncology, 13(11), pp. 1141–1151. Available at: https://doi.org/10.1016/S1470-2045(12)70425-4.
Hawsawi, Y.M., Al-Numair, N.S., Sobahy, T.M., Al-Ajmi, A.M., Al-Harbi, R.M., Baghdadi, M.A., Oyouni, A.A. and Alamer, O.M. (2019) ‘The role of BRCA1/2 in hereditary and familial breast and ovarian cancers’, Molecular Genetics and Genomic Medicine. Wiley-Blackwell. Available at: https://doi.org/10.1002/mgg3.879.
Hedau, S., Batra, M., Singh, U.R., Bharti, A.C., Ray, A. and Das, B.C. (2015) ‘Expression of BRCA1 and BRCA2 proteins and their correlation with clinical staging in breast cancer’, Journal of Cancer Research and Therapeutics, 11(1), pp. 158–163. Available at: https://doi.org/10.4103/0973-1482.140985.
Honrado, E., Benítez, J. and Palacios, J. (2004) ‘The Pathology of Hereditary Breast Cancer’, Hereditary Cancer in Clinical Practice, 2(3), pp. 131–138.
Huang, R.X. and Zhou, P.K. (2020) ‘DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer’, Signal Transduction and Targeted Therapy. Springer Nature. Available at: https://doi.org/10.1038/s41392-020-0150-x.
Hussein, I.A., Ahmed, S.T., Hameedi, A.D., Naji, R.Z., Alharbawi, L., Alkhaytt, M. and Pity, I.S. (2020) ‘Immunohistochemical expression of BRCA1 protein, ER, PR and Her2/neu in breast cancer: A clinicopathological study’, Asian Pacific Journal of Cancer Prevention, 21(4), pp. 1025–1029. Available at: https://doi.org/10.31557/APJCP.2020.21.4.1025.
International Agency for Research on Cancer (IARC), 2022. GLOBOCAN 2022: Estimated cancer incidence, mortality, and prevalence worldwide in 2022. Lyon, France: IARC. Available at: https://gco.iarc.fr
Kementerian Kesehatan Republik Indonesia. (2018). Hari Kanker Sedunia 2019: Deteksi Dini Selamatkan Jiwa. Diakses pada 11 Januari 2025, dari https://www.kemkes.go.id/id/hari-kanker-sedunia-2019
Kim, S.W., Roh, J. and Park, C.S. (2016) ‘Immunohistochemistry for pathologists: Protocols, pitfalls, and tips’, Journal of Pathology and Translational Medicine. Seoul National University, pp. 411–418. Available at: https://doi.org/10.4132/jptm.2016.08.08.
King, M.-C., Marks, J.H., Mandell, J.B., et al. (2003) Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2, SCIENCE. Available at: www.sciencemag.orgwww.sciencemag.org.
Long, D.T., Joukov, V., Budzowska, M. and Walter, J.C. (2014) ‘BRCA1 promotes unloading of the CMG Helicase from a stalled DNA replication fork’, Molecular Cell, 56(1), pp. 174–185. Available at: https://doi.org/10.1016/j.molcel.2014.08.012.
Mavaddat, N., Peock, S., Frost, D., et al. (2013) ‘Cancer risks for BRCA1 and BRCA2 mutation carriers: Results from prospective analysis of EMBRACE’, Journal of the National Cancer Institute, 105(11), pp. 812–822. Available at: https://doi.org/10.1093/jnci/djt095.
Miyamoto, K., Fukutomi, T., Asada, K., Wakazono, K., Tsuda, H., Asahara, T., Sugimura, T. and Ushijima, T. (2002) Promoter Hypermethylation and Post-transcriptional Mechanisms for Reduced BRCA1 Immunoreactivity in Sporadic Human Breast Cancers, Jpn J Clin Oncol.
Mook, S., Schmidt, M.K., Rutgers, E.J., et al. (2009) ‘Articles Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study’, www.thelancet.com/oncology, 10. Available at: https://doi.org/10.1016/S1470.
Mueller, C.R. and Roskelley, C.D. (2003) ‘Regulation of BRCA1 expression and its relationship to sporadic breast cancer’, Breast Cancer Research, pp. 45–52. Available at: https://doi.org/10.1186/bcr557.
Phung, M.T., Tin Tin, S. and Elwood, J.M. (2019) ‘Prognostic models for breast cancer: A systematic review’, BMC Cancer. BioMed Central Ltd. Available at: https://doi.org/10.1186/s12885-019-5442-6.
Radulescu, R.T. and Boenisch, T. (2007) ‘Blocking endogenous peroxidases: A cautionary note for immunohistochemistry: Letter to the Editor’, Journal of Cellular and Molecular Medicine, p. 1419. Available at: https://doi.org/10.1111/j.1582-4934.2007.00185.x.
Rakha, E.A., El-Sayed, M.E., Lee, A.H.S., et al. (2008) ‘Prognostic significance of nottingham histologic grade in invasive breast carcinoma’, Journal of Clinical Oncology, 26(19), pp. 3153–3158. Available at: https://doi.org/10.1200/JCO.2007.15.5986.
Rakha, E.A., El-Sheikh, S.E., Kandil, M.A., El-Sayed, M.E., Green, A.R. and Ellis, I.O. (2008) ‘Expression of BRCA1 protein in breast cancer and its prognostic significance’, Human Pathology, 39(6), pp. 857–865. Available at: https://doi.org/10.1016/j.humpath.2007.10.011.
Raouf, A., Zhao, Y., To, K., et al. (2008) ‘Transcriptome analysis of the normal human mammary cell commitment and differentiation process’, Cell Stem Cell, 3(1), pp. 109–118. Available at: https://doi.org/10.1016/j.stem.2008.05.018.
Rizzo, P., Osipo, C., Pannuti, A., Golde, T., Osborne, B. and Miele, L. (2009) ‘Targeting Notch signaling cross-talk with estrogen receptor and ErbB-2 in breast cancer’, Advances in Enzyme Regulation, 49(1), pp. 134–141. Available at: https://doi.org/10.1016/j.advenzreg.2009.01.008.
Roy, R., Chun, J. and Powell, S.N. (2012) ‘BRCA1 and BRCA2: Different roles in a common pathway of genome protection’, Nature Reviews Cancer, pp. 68–78. Available at: https://doi.org/10.1038/nrc3181.
Saputra Liambo, I., Frisitiohady, A., Hajrul Malaka, M., et al. (2022) ‘Review: Patofisiologi, Epidemiologi, dan Lini Sel Kanker Payudara Review: Pathophisiology, Epidemiology, and Cell Line of Breast Cancer’, Pharmauho: Jurnal Farmasi, 8(1). Available at: https://doi.org/10.33772/pharmauho.v8i.
Schlacher, K., Wu, H. and Jasin, M. (2012) ‘A Distinct Replication Fork Protection Pathway Connects Fanconi Anemia Tumor Suppressors to RAD51-BRCA1/2’, Cancer Cell, 22(1), pp. 106–116. Available at: https://doi.org/10.1016/j.ccr.2012.05.015.
Sharma, S., Kelly, T.K. and Jones, P.A. (2009) ‘Epigenetics in cancer’, Carcinogenesis, pp. 27–36. Available at: https://doi.org/10.1093/carcin/bgp220
Sulaeman, R. (2021) Riwayat Penggunaan Kontrasepsi Hormonal Pada Penderita Kanker Payudara. Available at: http://jkt.poltekkes-mataram.ac.id/index.php/home/index.
Sy, S.M.H., Huen, M.S.Y., Chen, J. and Livingston, D.M. (2009) PALB2 is an integral component of the BRCA complex required for homologous recombination repair, PNAS April.
Szczepanek, J., Skorupa, M., Jarkiewicz-Tretyn, J., Cybulski, C. and Tretyn, A. (2023) ‘Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA’, International Journal of Molecular Sciences. Multidisciplinary Digital Publishing Institute (MDPI). Available at: https://doi.org/10.3390/ijms24087235.
Tan, P.H., Ellis, I., Allison, K., et al. (2020) ‘The 2019 World Health Organization classification of tumours of the breast’, Histopathology. Blackwell Publishing Ltd, pp. 181–185. Available at: https://doi.org/10.1111/his.14091.
Verma, D., Agarwal, K. and Tudu, S. (2018) ‘Expression of breast cancer type 1 and its relation with expression of estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2/neu in breast carcinoma on trucut biopsy specimens’, Indian Journal of Pathology and Microbiology, 61(1), pp. 31–38. Available at: https://doi.org/10.4103/IJPM.IJPM_393_16.
Wang, F., Fang, Q., Ge, Z., Yu, N., Xu, S. and Fan, X. (2012) ‘Common BRCA1 and BRCA2 mutations in breast cancer families: A meta-analysis from systematic review’, Molecular Biology Reports, pp. 2109–2118. Available at: https://doi.org/10.1007/s11033-011-0958-0.
Wang, X., Zou, C., Zhang, Yi, et al. (2021) ‘Prediction of BRCA Gene Mutation in Breast Cancer Based on Deep Learning and Histopathology Images’, Frontiers in Genetics, 12. Available at: https://doi.org/10.3389/fgene.2021.661109.
Winters, S., Martin, C., Murphy, D. and Shokar, N.K. (2017) ‘Breast Cancer Epidemiology, Prevention, and Screening’, Progress in Molecular Biology and Translational Science, 151, pp. 1–32. Available at: https://doi.org/10.1016/BS.PMBTS.2017.07.002.
Yu, X., Christiano, C., Chini, S., He, M., Mer, G. and Chen, J. (2003) ‘The BRCT Domain Is a Phospho-Protein Binding Domain’, SCIENCE, 302, pp. 639–642.
Zhang, F., Fan, Q., Ren, K. and Andreassen, P.R. (2009) ‘PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2’, Molecular Cancer Research, 7(7), pp. 1110–1118. Available at: https://doi.org/10.1158/1541-7786.MCR-09-0123.
License
Copyright (c) 2025 Romy Healthy Mikailla, Novrita Padauleng, Rizka Vidya Lestari, Lale Maulin Prihatina, Bambang Priyanto, Baiq Ratna Kumaladewi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Jurnal Biologi Tropis is licensed under a Creative Commons Attribution 4.0 International License.
The copyright of the received article shall be assigned to the author as the owner of the paper. The intended copyright includes the right to publish the article in various forms (including reprints). The journal maintains the publishing rights to the published articles.
Authors are permitted to disseminate published articles by sharing the link/DOI of the article at the journal. Authors are allowed to use their articles for any legal purposes deemed necessary without written permission from the journal with an acknowledgment of initial publication to this journal.
